Peter MacCallum researchers are developing a potential new way to make CAR T-cell therapy more effective against breast cancer and other solid cancers. CAR T-cell therapy is a type of immunotherapy where a patient’s own immune cells are collected and reengineered, before being infused back into the patient to fight their cancer. But CAR T-cells
The approvals of the first gene and cell therapies in recent years have ushered in a new era of medicine. These cutting-edge approaches are poised to change the trajectory of how we treat cancer, fatal genetic conditions, and other devastating diseases. But these innovations also come with their own set of challenges, including issues of
All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. WHO, in collaboration with partners, expert networks, national authorities,
Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is the first comprehensive and systematic overview of cell therapies landscape by the company. This report is specifically focused on Stem Cell therapies and Chimeric Antigen Receptor T-cell (CAR-T) therapies, and it is the first
Scientific evidence that was used to inform the UK government’s key policies impacting millions of people during the first wave of COVID-19 including the rule of six and the first national stay-at-home order is published today [31 May] in the journal of the Royal Society. The Special Theme issue is compiled and guest edited by
